Lakewood-Amedex Q1 FY26 net loss widens to $923,291

• Lakewood-Amedex Biotherapeutics posted a net loss of USD 923,291 for the quarter ended March 31, 2026, widening from USD 539,617 a year earlier.
• Operating loss widened to USD 886,750 as operating expenses rose to USD 886,750 from USD 542,609.
• General and administrative costs climbed to USD 704,603 from USD 372,906, driven by higher professional fees and investor relations spending tied to preparation for a proposed Nasdaq direct listing.
• Research and development spending edged up to USD 182,147 from USD 169,703, while net interest expense increased as interest expense rose to USD 38,219 from USD 1,315.
• Cash and cash equivalents were USD 11,700 at March 31, 2026; it received about USD 6.8 million of net proceeds on April 21, 2026 from a private placement of Series C Convertible Preferred Stock and expects cash to fund operating needs through 2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Lakewood-Amedex Biotherapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001213900-26-060640), on May 22, 2026, and is solely responsible for the information contained therein.